Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus

episode

Neurology Minute not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

recent transcribed audio

NPR News: 09-19-2026 12AM EDT 5 min · 19 Sep 2026 · NPR News Now

12AM ET 09/19/2026 Newscast 3 min · 19 Sep 2026 · Fox News Hourly Update

NPR News: 09-18-2026 11PM EDT 5 min · 19 Sep 2026 · NPR News Now

The Augmentation Paradox 2 min · 19 Sep 2026 · Conspiracy Theories Exploring The Unseen

11PM ET 09/18/2026 Newscast 3 min · 19 Sep 2026 · Fox News Hourly Update

Preliminary Final Week - Crunch Time - Full Show (12.09.26) 1h 29m · 19 Sep 2026 · Crunch Time

Report any issue

Source

Recorded14 May 2019

Publisherneurologyminute.libsyn.com ↗

Handlerec:10219065

Show notes

Dr. Ivan Sanchez Fernandez discusses the main points from his paper on meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related